Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
References (70)
- et al.
Targeting the HER-kinase axis in cancer
Semin Oncol
(2004) - et al.
Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series
Bioorg Med Chem Lett
(2006) - et al.
and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
Ann Oncol
(2007) - et al.
A phase II study of lapatinib monotherapy in chemotherapy- refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
Ann Oncol.
(2008) Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer
Clin Lung Cancer
(2006)- et al.
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
Mayo Clin Proc
(2008) - et al.
Cancer statistics, 2007
CA Cancer J Clin
(2007) - et al.
Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: A randomized trial at the National Cancer Institute
J Clin Oncol
(1992) - et al.
HER-2/neu as a predictive marker of response to breast cancer therapy
Breast Cancer Res Treat
(1998) - et al.
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
Science
(1987)
Biology of interactions: Antiepidermal growth factor receptor agents
J Clin Oncol
(2007)
ErbB receptors: From oncogenes to targeted cancer therapies
J Clin Invest
(2007)
EGF-ERBB signalling: Towards the systems level
Nat Rev Mol Cell Biol
(2006)
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
J Clin Oncol
(2005)
Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor
Curr Top Med Chem
(2006)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
J Natl Cancer Inst
(2007)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb GW572016) in an expanded panel of human normal and tumour cell lines
Cell Prolif
(2007)
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
Mol Cancer Ther
(2001)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
Cancer Res
(2006)
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
Oncogene
(2005)
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling
Mol Cancer Ther
(2007)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
Endocrinology
(2003)
The dual ErbB1/ ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer
Cancer Res
(2005)
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
Invest New Drugs
(2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
J Clin Oncol
(2005)
A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients
Clin Pharmacol Ther.
(2007)
Lapatinib pharmacokinetics in pediatric patients with recurrent or refractory CNS tumors
Abstract presented at the 2007 AAPS Annual Meeting & Exposition
(2008)
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer
J Clin Oncol
(2008)
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
J Clin Oncol
(2007)
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer
Clin Cancer Res
(2008)
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
Clin Cancer Res
(2007)
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer
J Clin Oncol
(2008)
Cited by (313)
Detailed curriculum vitae of HER2-targeted therapy
2023, Pharmacology and TherapeuticsTargeting synthetic lethal paralogs in cancer
2023, Trends in CancerComplex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer
2023, Journal of Drug Delivery Science and TechnologyLapatinib: A comprehensive profile
2023, Profiles of Drug Substances, Excipients and Related Methodology
Copyright © 2008 Published by Elsevier Inc.